A polygenic and phenotypic risk prediction for polycystic ovary syndrome evaluated by phenomewide association studies

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

  • Yoonjung Yoonie Joo
  • Ky'Era Actkins
  • Jennifer A. Pacheco
  • Anna O. Basile
  • Robert Carroll
  • David R. Crosslin
  • Felix Day
  • Joshua C. Denny
  • Digna R.Velez Edwards
  • Hakon Hakonarson
  • John B. Harley
  • Scott J. Hebbring
  • Kevin Ho
  • Gail P. Jarvik
  • Michelle Jones
  • Frank D. Mentch
  • Cindy Meun
  • Bahram Namjou
  • Sarah Pendergrass
  • Marylyn D. Ritchie
  • Ian B. Stanaway
  • Margrit Urbanek
  • Theresa L. Walunas
  • Maureen Smith
  • Rex L. Chisholm
  • Abel N. Kho
  • Lea Davis
  • M. Geoffrey Hayes

Context: As many as 75% of patients with polycystic ovary syndrome (PCOS) are estimated tobe unidentified in clinical practice. Objective: Utilizing polygenic risk prediction, we aim to identify the phenome-widecomorbidity patterns characteristic of PCOS to improve accurate diagnosis and preventivetreatment.Design, Patients, and Methods: Leveraging the electronic health records (EHRs) of 124 852individuals, we developed a PCOS risk prediction algorithm by combining polygenic risk scores(PRS) with PCOS component phenotypes into a polygenic and phenotypic risk score (PPRS). Weevaluated its predictive capability across different ancestries and perform a PRS-based phenomewide association study (PheWAS) to assess the phenomic expression of the heightened risk ofPCOS.Results: The integrated polygenic prediction improved the average performance (pseudo-R2)for PCOS detection by 0.228 (61.5-fold), 0.224 (58.8-fold), 0.211 (57.0-fold) over the null modelacross European, African, and multi-ancestry participants respectively. The subsequent PRSpowered PheWAS identified a high level of shared biology between PCOS and a range ofmetabolic and endocrine outcomes, especially with obesity and diabetes: "morbid obesity","type 2 diabetes", "hypercholesterolemia", "disorders of lipid metabolism", "hypertension",and "sleep apnea" reaching phenome-wide significance.Conclusions: Our study has expanded the methodological utility of PRS in patient stratificationand risk prediction, especially in a multifactorial condition like PCOS, across different geneticorigins. By utilizing the individual genome-phenome data available from the EHR, our approachalso demonstrates that polygenic prediction by PRS can provide valuable opportunities todiscover the pleiotropic phenomic network associated with PCOS pathogenesis.Abbreviations: AA, African ancestry; ANOVA, analysis of variance; BMI, body mass index; EA,European ancestry; EHR, electronic health records; eMERGE, electronic Medical Records andGenomics Network; GWAS, genome-wide association study; IBD, identity-by-descent; ICDCM, International Classification of Diseases, Clinical Modification; LD, linkage disequilibrium;MA, multi-ancestry; MAF, minor allele frequency; NIH, National Institutes of Health; PCA,principal component analysis; PheWAS, phenome-wide association study; PCOS, polycysticovary syndrome; PPRS, polygenic and phenotypic risk score; PRS, polygenic risk score; RAF, riskallele frequency; ROC, receiving operating characteristic; SNV, single nucleotide variant.

OriginalsprogEngelsk
TidsskriftJournal of Clinical Endocrinology and Metabolism
Vol/bind105
Udgave nummer6
Antal sider19
ISSN0021-972X
DOI
StatusUdgivet - 2020
Eksternt udgivetJa

Bibliografisk note

Publisher Copyright:
© Endocrine Society 2020. All rights reserved.

ID: 301621434